Indication intelligence, analysis and sector perception

StemCells (STEM) cervical spine injury study shows encouraging results

April 18, 2016 9:42am

Final Results for the first Six Patients to be released later this quarter

Shares were up 21% premarket and trading falling to +12.27% or +$0.03 to $0.26

Positive interim data from a P2 study, Pathway, assessing its HuCNS-SC human neural stem cells for the treatment of chronic cervical spinal cord injury

The results were presented at the 2016 American Spinal Injury Association annual meeting in Philadelphia.

The Bottom Line: At month six, five of six patients in Cohort I showed an improvement in muscle strength while four of the five demonstrated improved performance on functional tests assessing dexterity and fine motor skills. Also, four of the six showed improvement in the level of cord injury as measured by standards called ISNCSCI. Twelve-month data on the first open-label cohort will be released later this quarter.

STEM has currently enrolled and randomized 19 of the 40 total subjects in the statistically powered, single-blind Cohort II. Enrollment should be completed in September with final results expected in 2017.

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

2 hours 8 min ago
RegMed Investors’ (RMi) pre-open: head and knee down

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.